- Generic name
- Levetiracetam
- Strength
- 500 mg/5 ml
- Dosage form
- Injection
- Manufactured by
- Renata PLC.
Epicet 500/5 Injection Injection
About Epicet 500/5 Injection
Epicet 500/5 Injection is a hospital-use form of levetiracetam, a medicine that helps steady the electrical activity of the brain and reduce seizures. It is given by a healthcare professional when the injection route is needed.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Epicet 500/5 Injection?
Epicet 500/5 Injection is an anti-epileptic medicine made by Renata PLC. It contains levetiracetam, a type of drug that acts on the brain to help control abnormal electrical signals that cause seizures. It is used as add-on treatment for partial-onset seizures, and as sole treatment in some newly diagnosed adults and adolescents. The injection form allows the medicine to be given when tablets or oral liquid cannot be taken. It belongs to a group called adjunct anti-epileptic drugs. The doctor decides the dose and course for each person.
Uses of Epicet 500/5 Injection
Epicet 500/5 Injection is used to treat partial-onset seizures, which start in one part of the brain and may or may not spread to the whole body. It is given as add-on therapy in adults, adolescents, children and infants from one month of age. It can also be used alone in newly diagnosed epilepsy in adults and adolescents from sixteen years of age. Whether it suits a particular person is a decision for the doctor.
How to use Epicet 500/5 Injection
Epicet 500/5 Injection is given by a doctor or nurse, usually in a hospital or clinic. It is not a medicine to use at home. The doctor decides the dose, how often it is given, and for how long, based on the person's condition and response. Never change or stop the schedule on your own. If a dose is missed, tell the treating team so they can advise. Tell the staff about all other medicines being taken.
Side effects of Epicet 500/5 Injection
Side effects seen with levetiracetam include drowsiness, weakness, infection and dizziness in adults. In children, tiredness, aggression, nasal congestion, reduced appetite and irritability have been reported. Because this is an injection given under medical care, staff watch for reactions. Tell the doctor or nurse promptly about unusual sleepiness, mood or behaviour changes, fever, or any reaction at the injection site. Ask the doctor about anything that worries you.
Safety and precautions
Tell the doctor before treatment if there is kidney or liver problems, since the dose may need review. Levetiracetam is not recommended in pregnancy or in women who could become pregnant and are not using contraception, unless the doctor considers it necessary. It passes into breast milk, so breastfeeding is not recommended unless the doctor decides the benefit outweighs the risk. People allergic to levetiracetam or related substances should not receive it. Always mention other medicines, including epilepsy medicines, to the doctor.
Frequently asked questions
What does the strength 500 mg/5 ml mean on this injection?
The strength shows how much levetiracetam is present in each 5 ml of the injection solution. The doctor uses this information to decide the dose for the patient. Do not work out or adjust any dose yourself.
What is Epicet 500/5 Injection used for and what kind of medicine is it?
It is an anti-epileptic medicine containing levetiracetam. It is used for partial-onset seizures, as add-on treatment in several age groups, and alone in some newly diagnosed adults and adolescents. The doctor decides if it is suitable.
What side effects should I watch for, and when should I call the doctor?
Watch for drowsiness, weakness, dizziness, infection, or in children tiredness, aggression, irritability and poor appetite. Call the doctor about unusual sleepiness, mood or behaviour changes, fever, or any reaction at the injection site. Ask about anything unclear.
Can I or my family give this injection at home?
No. Epicet 500/5 Injection is given by a trained healthcare professional, usually in a hospital or clinic. The doctor or nurse decides how it is given and monitors the patient. Ask the treating team any questions about the schedule.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.